Please login to the form below

Not currently logged in
Email:
Password:

Spinraza

This page shows the latest Spinraza news and features for those working in and with pharma, biotech and healthcare.

Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma

Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma

The RESPOND study aims to evaluate if Spinraza can benefit SMA patients who have experienced a ‘suboptimal’ response to Zolgensma (onasemnogene abeparvovec). ... Our hope is that results from RESPOND will demonstrate if Spinraza can optimise

Latest news

More from news
Approximately 20 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • #OrkambiNow? #OrkambiNow?

    But Orkambi is not the only orphan disease drug stuck in market access limbo in the England – Biogen’s Spinraza and BioMarin’s Kuvan are both currently suffering similar fates, and

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    only other SMA treatment available, Biogen’s Spinraza. ... The company argues that current ten- year costs of caring for SMA type 1 patients with Spinraza and additional care costs are somewhere between $2.5-$5m.

  • No incentive for a cure No incentive for a cure

    And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to  the health of motor ... And the lack of affordability - as well as the bad

  • The good, the bad and the ugly The good, the bad and the ugly

    Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    2015 and in the EU 2016) and Spinraza (for the treatment of spinal muscular atrophy, only approved in the US).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • Article: Market access in Brazil

    All eyes on Spinraza. Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil? ... In April 2019, Brazilian Health Minister Luiz Henrique

  • Research Partnership

    All eyes on Spinraza. Download our pre-launch checklist.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics